Cargando…
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
Activating mutations in CD79 and MYD88 have recently been found in a subset of diffuse large B-cell lymphoma (DLBCL), identifying B-cell receptor and MYD88 signalling as potential therapeutic targets for personalized treatment. Here, we report the prevalence of CD79B and MYD88 mutations and their re...
Autores principales: | Kraan, W, Horlings, H M, van Keimpema, M, Schilder-Tol, E J M, Oud, M E C M, Scheepstra, C, Kluin, P M, Kersten, M J, Spaargaren, M, Pals, S T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789201/ https://www.ncbi.nlm.nih.gov/pubmed/24013661 http://dx.doi.org/10.1038/bcj.2013.28 |
Ejemplares similares
-
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014) -
The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells
por: van Keimpema, Martine, et al.
Publicado: (2017) -
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
por: Vermaat, Joost S., et al.
Publicado: (2020) -
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
por: Minderman, Marthe, et al.
Publicado: (2023) -
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
por: Visco, Carlo, et al.
Publicado: (2020)